![](https://investorshub.advfn.com/uicon/19649.png?cb=1607617291)
Tuesday, June 22, 2021 6:48:21 PM
-Redemsivir with Baricitinib request filed 10/07/20, approved 11/19/20 (44 days or 6 weeks, 2 days)
-Casirivimab with Imdevimab request filed 10/09/20, approved 11/21/20 (44 days or 6 weeks, 2 days)
-Bamlanivimab request filed 10/08/20, approved 11/09/20. (33 days or 4 weeks, 5 days)
-Bamlanivimab and Etesevimab -
Blaze Trial ended 1/26/2021 EUA approved 02/09/2021. (15 days from trials end)
-Sotrovimab filed 3/10/ 2021 or later in March, approved 5/26/2021 (78 days or 11 weeks + 1 day)
So we have 44 days twice, 33 days 78 days (or less), 15 days from end of a trial.
~ Money Making Money ~
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM